Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Samplix ApS. (1/10/19). "Press Release: Samplix Wins €1.9 Million in Prestigious Horizon 2020 – SME Instrument Program".

Region Region EU (European Union)
Organisations Organisation Samplix ApS
  Organisation 2 European Commission (EC)
  Group EU (govt)
Products Product sample preparation (technology)
  Product 2 DNA/RNA sequencing
Persons Person Kongsbak, Lars (Samplix 201901 CEO before Exiqon 2003–2017 CEO)
  Person 2 Christensen, Hans Henrik Chrois (Samplix 201901 CFO before Exiqon 200708 CFO)

Today, Samplix announced that the company has been selected by the European Commission among the winners of the prestigious Horizon 2020 – SME Instrument program, obtaining €1.9 million to mature its proprietary Xdrop™ technology. The selection process was highly competitive with more than 1.800 applicants and a success rate of only about 3%.

Samplix’ proprietary Xdrop™ technology comprises novel microfluidics, chemistry and bioinformatics in a simple work process that allows scientists and clinicians to partition millions of single molecules in droplets, thereby enabling both targeted enrichment and highquality amplification of single molecules for sequencing analysis.

The Xdrop™ technology is currently in beta test at leading research institutions world-wide.

“We are excited to receive recognition and support by the European Commission for completion of our product development towards commercial launch of the Xdrop™ solution later this year” said CEO Lars Kongsbak.

About Horizon 2020 EU funding

Horizon 2020 EU funding supports Small and Medium-sized Enterprises (SME) with breakthrough innovation projects and a market-creating potential. The highly competitive fund is only offered to SMEs which fall under European Innovation Council’s (EIC) SME definition. The fund is part of the Horizon 2020 work programme 2018-2020, funding highpotential innovations in the EU. The fund offers Europe’s brightest and boldest innovators the funding for breakthrough ideas with the potential to create entirely new markets or revolutionise existing ones.

About Samplix

At Samplix, we aspire to become the leading provider of solutions for single molecule sample preparation for DNA sequencing analysis. Our mission is to improve healthcare by transforming how today’s multibillion industry operates its installed base of DNA sequencers.

Lars Kongsbak, CEO: + 45 40902101
Hans Henrik Chrois Christensen, CFO: +45 40902131

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Samplix ApS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top